concordance of krasbraf mutation status in metastatic colorectal cancer before and after anti-egfr therapy和合krasbraf突变状态的转移性结直肠癌anti-egfr之前和之后的治疗.pdfVIP

Hindawi Publishing Corporation Journal of Oncology Volume 2009, Article ID 831626, 8 pages doi:10.1155/2009/831626 Research Article Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy ¨ 1 1 2 3 4 5 S. Gattenlohner, B. Etschmann, V. Kunzmann, A. Thalheimer, M. Hack, G. Kleber, 2 2 ¨ 1 H. Einsele, C. Germer, and H.-K. Muller-Hermelink 1 Institute of Pathology, University of Wurzburg, 97080 Wurzburg, Germany ¨ ¨ 2 Department of Internal Medicine II, University of Wurzburg, 97080 Wurzburg, Germany ¨ ¨ 3 Department of Surgery, University of Wurzburg, 97080 Wurzburg, Germany ¨ ¨ 4 Institute of Pathology, Ostalb-Klinikum Aalen, 73430 Aalen, Germany 5 Department of Internal Medicine, Ostalb-Klinikum Aalen, 73430 Aalen, Germany ¨ Correspondence should be addressed to S. Gattenlohner, stefan.gattenloehner@mail.uni-wuerzburg.de Received 30 August 2009; Revised 9 November 2009; Accepted 31 December 2009 Recommended by Francis Seow-Choen Anti-EGFR targeted therapy is a potent strategy in the treatment of metastatic colorectal cancer (mCRC) but activating mutations in the KRAS gene are associated with poor response to this treatment. Therefore, KRAS mutation analysis is employed in the selection of pa